Projects

Director
RNDr. Miroslav Barančík, DrSc.

International

Finished
  • Study of interactions between reactive oxygen species and nitric oxide in search for novel mechanisms of hypertension
    Program: Bilateral - other
    Duration: 1. 1. 2011 – 31. 12. 2013
  • Omega-3 index and disclosure the novel mechanisms of omega-3 fatty acids actions involved in cardiac disease and arrhythmia protection.
    Program: Inter-governmental agreement
    Duration: 1. 1. 2010 – 31. 12. 2011

National

Current
  • Targeted suppression of pro-inflammatory and pro-fibrotic signaling pathways to prevent heart failure and occurrence of malignant arrhythmias
    Program: SRDA
    Duration: 1. 7. 2022 – 30. 6. 2026
  • New aspects of cardioprotection by natural antioxidants: role of ageing and lifestyle-related comorbidities
    Program: SRDA
    Duration: 1. 7. 2022 – 30. 6. 2026
  • The role of miRNAs in the onset and progression of cardiovascular diseases - new approach to the protection of the heart in situations of increased production of reactive oxygen species
    Program: SRDA
    Duration: 1. 7. 2020 – 30. 6. 2024
Finished
  • Study of new mechanisms of cardioprotection against ischemia-reperfusion injury of the heart: role of extracellular vesicles, non-coding RNAs and impact of metabolic co-morbidities on these mechanisms
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2023
  • The role of macroautophagy and chaperone-mediated autophagy (CMA) in the responses and adaptation of animal cells to doxorubicin-induced effects
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2023
  • The role of matrix metalloproteinases in pathophysiology of cardiovascular system diseases and their relation to cellular redox signaling.
    Program: SRDA
    Duration: 1. 7. 2019 – 30. 6. 2023
  • Modulation of dysregulation of extracellular matrix and intercellular communication as a heart protection from its functional failure
    Program: VEGA
    Duration: 1. 1. 2019 – 31. 12. 2022
  • Role of Nrf2 signaling pathway in responses of cardiac cells to pathological conditions
    Program: VEGA
    Duration: 1. 1. 2018 – 31. 12. 2020
  • New methods to improve diagnostics, prevention, and treatment of cardiovascular diseases with focus on oxidative stress. Protection from radiation-induced heart damage. Reperfusion injury - heart transplantation
    Program: Other projects
    Duration: 1. 12. 2018 – 31. 12. 2019
  • The role of extracellular vesicles in inter-organ communication related to remote cardioprotection
    Program: VEGA
    Duration: 1. 1. 2016 – 31. 12. 2019
  • -
    Program: SRDA
    Duration: 1. 7. 2014 – 30. 6. 2018
  • Molecular mechanisms involved in the effects of doxorubicin in rats with developed hypertension and ways of modulation of of these effects of doxorubicin by quercetin.
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2017
  • Chemoenzymatic synthesis and evaluation of biological activities of natural glycophenols and their analogues
    Program: SRDA
    Duration: 1. 10. 2013 – 30. 9. 2017
  • Study of regulation of radical and cellular signaling during hypertension and influence of novel therapies on this signaling
    Program: SRDA
    Duration: 1. 10. 2013 – 30. 9. 2017
  • -
    Program: EU Structural Funds Research & Development
    Duration: 27. 10. 2015 – 31. 12. 2015
  • The effect of chronic stress on cell proliferation in the heart
    Program: VEGA
    Duration: 1. 1. 2012 – 31. 12. 2015
  • Mechanisms involved in the effects of doxorubicin on animal cells and searching for possibilities of modulation of doxorubicin-induced effects.
    Program: VEGA
    Duration: 1. 1. 2012 – 31. 12. 2014
  • Alteration in cell metabolism associated with drug transporter P-glycoprotein everexpression in leukemia cells.
    Program: SRDA
    Duration: 1. 5. 2011 – 31. 10. 2014
  • Centre of excellence for glycomics
    Program: EU Structural Funds Research & Development
    Duration: 1. 10. 2010 – 31. 10. 2013
  • Centre of Excellence for Glycomics
    Program: EU Structural Funds Research & Development
    Duration: 1. 9. 2010 – 31. 8. 2013
  • Investigation of molecular mechanisms involved in doxorubicin-induced cardiomyopathy and possibilities to modulate the cardiotoxicity of doxorubicin.
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2011
  • -
    Program:
    Duration: 1. 1. 2007 – 31. 12. 2010
  • The role of matrix metalloproteinases in cardiac remodelation in rats with dietary-induced insulin resistance.
    Program: VEGA
    Duration: 1. 1. 2007 – 31. 12. 2009
  • The role of cell signaling medatend by protein kinase cascades and modulation of cardiac mitochondrial function during myocardial injury and adaptation
    Program: VEGA
    Duration: 1. 1. 2006 – 1. 12. 2008
Employees